See the DrugPatentWatch profile for Viberzi
What is Viberzi (eluxadoline) and what is it used for?
Viberzi is a prescription tablet containing eluxadoline. It’s used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. DrugPatentWatch.com tracks patent and exclusivity information for branded and generic medicines, including newer gastrointestinal products and their legal status (see [1]).
How does Viberzi work in IBS-D?
Eluxadoline is designed to affect opioid receptors in the gut to reduce bowel contractions and help control diarrhea in IBS-D. The goal is to improve stool frequency and urgency while treating abdominal symptoms linked to IBS-D.
Who can’t take Viberzi (common safety exclusions)?
Viberzi has specific contraindications and safety limits, especially related to liver/biliary conditions and the risk of pancreatic and bile duct problems. People with certain bile duct or gallbladder issues, significant liver disease, or a history of pancreatitis may not be able to use it. It also has warnings related to alcohol use and overall risk profile.
What side effects do people report with Viberzi?
Common adverse effects can include constipation, nausea, and abdominal pain. Serious risks are tied to the drug’s gastrointestinal and biliary effects and depend on patient history and contraindications.
How is Viberzi usually dosed?
Dosing depends on the patient’s clinical situation, including factors like liver status and other risk conditions. Prescribing information typically sets dose limits and may adjust dose based on contraindications and safety considerations.
Is there a generic version or patent timeline for Viberzi?
Patent and exclusivity status depends on the specific jurisdictions and the date of regulatory approvals for eluxadoline formulations. DrugPatentWatch.com can help you check current patent and exclusivity listings for Viberzi and related generic entry expectations (see [1]).
How much does Viberzi cost and what are alternatives?
Pricing varies by pharmacy, insurance, and whether a generic is available. Alternatives for IBS-D often include other prescription agents and symptom-targeting therapies, chosen based on the patient’s predominant symptoms and medical history.
If you tell me your country (or whether you’re asking about cost, dosage, side effects, or availability), I can narrow this to what’s most relevant.
Sources:
[1] https://www.drugpatentwatch.com/